{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Reimer T"],"pubmed_abstract":["The sub-study of the INSEMA trial (randomization-2) compares completion axillary lymph node dissection (cALND) with sentinel lymph node biopsy (SLNB) alone in cN0 patients with T1/T2 invasive breast cancer and one to three sentinel node macrometastases undergoing upfront breast-conserving surgery. The key secondary objective is to assess whether the SLNB-alone arm is non-inferior to cALND in terms of invasive disease-free survival (iDFS). Finally, 485 patients were recruited, and 386 patients (cALND: N = 169, SLNB alone: N = 217) were included in the per-protocol set. The median follow-up is 74.2 months. The 5-year iDFS analysis in the per-protocol set demonstrates a non-significant difference between study arms, with a hazard ratio (HR) of 1.69 (95% CI: 0.98-2.94) for SLNB alone compared "],"journal":["NPJ breast cancer"],"pagination":["19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12855813"],"repository":["biostudies-literature"],"pubmed_title":["Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial."],"pmcid":["PMC12855813"],"pubmed_authors":["Marme F","Krug D","Reimer T","Kuehn T","Gerber B","Loibl S","Knauer M","Ruth S","Denkert C","Holtschmidt J","Golatta M","Stahl N","Veselinovic K","Ataseven B","Stachs A","Nekljudova V","Heil J","Trapp E","Reitsamer R","Bekes I","Strittmatter HJ","Polata S","Hildebrandt G","Thill M","Mueller T","Zahm DM"],"additional_accession":[]},"is_claimable":false,"name":"Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.","description":"The sub-study of the INSEMA trial (randomization-2) compares completion axillary lymph node dissection (cALND) with sentinel lymph node biopsy (SLNB) alone in cN0 patients with T1/T2 invasive breast cancer and one to three sentinel node macrometastases undergoing upfront breast-conserving surgery. The key secondary objective is to assess whether the SLNB-alone arm is non-inferior to cALND in terms of invasive disease-free survival (iDFS). Finally, 485 patients were recruited, and 386 patients (cALND: N = 169, SLNB alone: N = 217) were included in the per-protocol set. The median follow-up is 74.2 months. The 5-year iDFS analysis in the per-protocol set demonstrates a non-significant difference between study arms, with a hazard ratio (HR) of 1.69 (95% CI: 0.98-2.94) for SLNB alone compared ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-14T05:33:10.913Z","creation":"2026-06-14T03:09:25.566Z"},"accession":"S-EPMC12855813","cross_references":{"pubmed":["41593108"],"doi":["10.1038/s41523-026-00902-7"]}}